BRD4: A Potential Drug Target and Biomarker for Various Diseases

Target Name: BRD4

NCBI ID: G23476

BRD4

BRD4: A Potential Drug Target and Biomarker for Various Diseases

BRD4 (Browne-Rothson disease gene 4), also known as Chromosome-Associated Protein 4, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. BRD4 is a transmembrane protein that is expressed in most tissues of the body and is involved in various cellular processes, including cell growth, differentiation, and survival.

BRD4 is a tumor suppressor gene that has been implicated in the development and progression of many types of cancer, including breast, ovarian, and prostate cancers. It has been shown to play a role in the regulation of cell cycle progression, apoptosis (programmed cell death), angiogenesis (the formation of new blood vessels), and stem cell maintenance.

BRD4 has also been linked to various other diseases, including neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases, as well as autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Due to its involvement in so many different diseases and its potential as a drug target, BRD4 has become a focus of intense research in recent years. Researchers have identified numerous potential drug targets and biomarkers for BRD4, including small molecules, peptides, and antibodies.

One of the most promising potential drug targets for BRD4 is the inhibition of its activity, known as inhibition of BRD4-associated protein (IAP), which has been shown to have anti-cancer effects in various preclinical studies. IAPs are proteins that interact with BRD4 and can inhibit its activity, potentially leading to the suppression of cancer cell growth and the inhibition of tumor progression.

Another potential drug target for BRD4 is the targeting of its downstream signaling pathways, such as the PI3K/Akt signaling pathway. This pathway is involved in the regulation of various cellular processes, including cell survival, angiogenesis, and inflammation. By inhibiting the activity of this pathway, researchers hope to reduce the risk of cancer cell proliferation and promote the growth of healthy tissues.

BRD4 has also been shown to be a potential biomarker for various diseases, including cancer. Its expression has been detected in a variety of tissues and has been linked to the development and progression of many types of cancer. By using techniques such as qRT-PCR , researchers have been able to demonstrate that BRD4 is expressed in a wide range of cancer types and that its expression is associated with poor prognosis in cancer patients.

In addition to its potential as a drug target and biomarker, BRD4 is also of interest as a potential therapeutic approach. Researchers have been exploring the use of small molecules and antibodies to target BRD4 and have shown that some of these treatments have the potential to be effective in preclinical studies.

Overall, BRD4 is a gene that has the potential to be a valuable drug target and biomarker for a wide range of diseases. Its involvement in the regulation of cell cycle progression, apoptosis, angiogenesis, and stem cell maintenance makes it an attractive target for the development of new therapeutic approaches. Further research is needed to fully understand the role of BRD4 in disease and to develop effective treatments.

Protein Name: Bromodomain Containing 4

Functions: Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure (PubMed:23589332, PubMed:23317504, PubMed:22334664). During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P-TEFb complex and recruiting it to promoters. Also recruits P-TEFb complex to distal enhancers, so called anti-pause enhancers in collaboration with JMJD6. BRD4 and JMJD6 are required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P-TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II (PubMed:23589332, PubMed:19596240, PubMed:16109377, PubMed:16109376, PubMed:24360279). Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II (PubMed:23086925). According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo (PubMed:22509028). In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B (PubMed:19103749). Also acts as a regulator of p53/TP53-mediated transcription: following phosphorylation by CK2, recruited to p53/TP53 specific target promoters (PubMed:23317504)

The "BRD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets